• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Announces Unaudited First Quarter 2024 Financial Results

    5/17/24 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    SHENZHEN, China, May 17, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the first quarter ended March 31, 2024.

    First Quarter 2024 Financial Highlights

    • Net revenues were RMB551.6 million (US$76.4 million) in the first quarter of 2024, compared with RMB188.9 million in the same period of 2023.
    • Gross margin was 25.9% in the first quarter of 2024, compared with 24.2% in the same period of 2023.
    • U.S. GAAP net income was RMB132.6 million (US$18.4 million) in the first quarter of 2024, compared with U.S. GAAP net loss of RMB56.3 million in the same period of 2023.
    • Non-GAAP net income[1] was RMB207.5 million (US$28.7 million) in the first quarter of 2024, compared with RMB183.6 million in the same period of 2023.

    "We started 2024 with a steady first quarter," commented Ms. Ying (Kate) Wang, Co-founder, Chairperson of the Board of Directors, and Chief Executive Officer of RLX Technology. "Our international business is developing positively as we refine our regional strategies. Despite challenges posed by regulatory changes across various regions, we continue to identify opportunities and leverage our core strengths to prudently enter potential markets. Domestically, we are encouraged by the positive impact of China's recent regulatory crackdown on illegal products, but much progress remains to be made. We remain committed to collaborating with regulators and advocating for a well-regulated and healthy e-vapor industry. As a trusted e-vapor brand for adult smokers, we are dedicated to optimizing our product portfolio with premium, compliant, and innovative products that meet our users' needs and drive growth in this evolving industry."

    Mr. Chao Lu, Chief Financial Officer of RLX Technology, commented, "In the first quarter, net revenues increased to RMB551.6 million, marking our fifth consecutive quarter of sequential revenue growth. Our gross margin improved by 170 basis points year-over-year to 25.9%, thanks to our supply chain efficiency enhancements. Furthermore, excluding the impact of share-based compensation, our non-GAAP operating profit remained positive, bolstered by an increasing contribution from our international operations, compared to a RMB133.3 million loss recorded in the same quarter last year. With our resilient business model, effective regional strategies, and consistent strong execution, we are confident of sustaining this growth trajectory and delivering sustainable value to our stakeholders."

    First Quarter 2024 Financial Results

    Net revenues were RMB551.6 million (US$76.4 million) in the first quarter of 2024, compared with RMB188.9 million in the same period of 2023. The increase was primarily due to our international expansion.

    Gross profit was RMB142.8 million (US$19.8 million) in the first quarter of 2024, compared with RMB45.7 million in the same period of 2023.

    Gross margin was 25.9 % in the first quarter of 2024, compared with 24.2% in the same period of 2023. This improvement was primarily driven by our supply chain efficiency enhancements, partially offset by an increase in inventory provision and an unfavorable shift in the revenue mix.

    Operating expenses were RMB194.4 million (US$26.9 million) in the first quarter of 2024, compared with RMB418.9 million in the same period of 2023. The decrease was primarily due to a decrease in share-based compensation expenses, from RMB240.0 million in the first quarter of 2023 to RMB74.9 million (US$10.4 million) in the same period of 2024, along with a decrease in salaries and welfare benefits. The changes in share-based compensation expenses were primarily due to the changes in the fair value of the share incentive awards that the Company granted to its employees with the fluctuations of the Company's share price.

    Selling expenses were RMB52.9 million (US$7.3 million) in the first quarter of 2024, compared with RMB85.8 million in the same period of 2023, primarily due to a decrease in salaries, welfare benefits and share-based compensation expenses.

    General and administrative expenses were RMB110.0 million (US$15.2 million) in the first quarter of 2024, compared with RMB256.5 million in the same period of 2023, mainly driven by a decrease in share-based compensation expenses, salaries, and welfare benefits.

    Research and development expenses were RMB31.5 million (US$4.4 million) in the first quarter of 2024, compared with RMB76.7 million in the same period of 2023, mainly driven by a decrease in salaries, welfare benefits and share-based compensation expenses.

    Loss from operations was RMB51.6 million (US$7.1 million) in the first quarter of 2024, compared with RMB373.2 million in the same period of 2023.

    Income tax expense was RMB16.3 million (US$2.3 million) in the first quarter of 2024, compared with income tax benefit of RMB17.6 million in the same period of 2023.

    U.S. GAAP net income was RMB132.6 million (US$18.4 million) in the first quarter of 2024, compared with U.S. GAAP net loss of RMB56.3 million in the same period of 2023.

    Non-GAAP net income was RMB207.5 million (US$28.7 million) in the first quarter of 2024, compared with RMB183.6 million in the same period of 2023.

    U.S. GAAP basic and diluted net income per American depositary share ("ADS") were RMB0.106 (US$0.015) and RMB0.101 (US$0.014), respectively, in the first quarter of 2024, compared with U.S. GAAP basic and diluted net loss per ADS of RMB0.043, in the same period of 2023.

    Non-GAAP basic and diluted net income per ADS[2] were RMB0.166 (US$0.023) and RMB0.159 (US$0.022), respectively, in the first quarter of 2024, compared with non-GAAP basic and diluted net income per ADS of RMB0.139 and RMB0.136, respectively, in the same period of 2023.

    Balance Sheet and Cash Flow

    As of March 31, 2024, the Company had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, net, long-term bank deposits, net and long-term investment securities, net of RMB14,681.4 million (US$2,033.3 million), compared with RMB15,138.4 million as of December 31, 2023. In the first quarter of 2024, net cash generated from operating activities was RMB4.0 million (US$0.6 million).

    Conference Call

    The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 17, 2024 (8:00 PM Beijing/Hong Kong Time on May 17, 2024).

    Dial-in details for the earnings conference call are as follows:

    United States (toll-free):

    +1-888-317-6003

    International:

    +1-412-317-6061

    Hong Kong, China (toll-free):

    +800-963-976

    Hong Kong, China:

    +852-5808-1995

    Mainland China:

    400-120-6115

    Participant Code:

    5404850

    Participants should dial in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." with the Participant Code as set forth above.

    Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com.

    A replay of the conference call will be accessible approximately two hours after the conclusion of the call until May 24, 2024, by dialing the following telephone numbers:

    United States:

    +1-877-344-7529

    International:

    +1-412-317-0088

    Replay Access Code:

    5345683

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, product development capabilities and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Non-GAAP Financial Measures

    The Company uses non-GAAP net income and non-GAAP basic and diluted net income per ADS, each a non-GAAP financial measure, in evaluating its operating results and for financial and operational decision-making purposes. Non-GAAP net income represents net income excluding share-based compensation expenses. Non-GAAP basic and diluted net income per ADS is computed using non-GAAP net income attributable to RLX Technology Inc. and the same number of ADSs used in U.S. GAAP basic and diluted net income per ADS calculation.

    The Company presents these non-GAAP financial measures because they are used by the management to evaluate its operating performance and formulate business plans. The Company believes that they help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that are included in net income. The Company also believes that the use of the non-GAAP measures facilitates investors' assessment of its operating performance, as they could provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by the management in its financial and operational decision making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. They should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per ADS or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review its historical non-GAAP financial measures to the most directly comparable U.S. GAAP measures. The non-GAAP financial measures here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on any single financial measure.

    For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliation of GAAP and non-GAAP Results" set forth at the end of this press release.

    Exchange Rate Information

    This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.2203 to US$1.00, the exchange rate on March 29, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward- looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in global e-vapor market; changes in its revenues and certain cost or expense items; governmental policies, laws and regulations across various jurisdictions relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    For more information, please contact:

    In China:

    RLX Technology Inc.

    Head of Capital Markets

    Sam Tsang

    Email: [email protected]

    Piacente Financial Communications

    Jenny Cai

    Tel: +86-10-6508-0677

    Email: [email protected]

    In the United States:

    Piacente Financial Communications

    Brandi Piacente

    Tel: +1-212-481-2050

    Email: [email protected]

     

    [1] Non-GAAP net income is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    [2] Non-GAAP basic and diluted net income per ADS is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands)











    As of



    December 31,

    March 31,

    March 31,



    2023

    2024

    2024



    RMB

    RMB

    US$

    ASSETS







    Current assets:







    Cash and cash equivalents

    2,390,298

    2,322,277

    321,632

    Restricted cash

    29,760

    52,484

    7,269

    Short-term bank deposits, net

    2,631,256

    2,320,529

    321,390

    Receivables from online payment platforms

    6,893

    7,284

    1,009

    Short-term investments, net

    3,093,133

    2,691,275

    372,737

    Accounts and notes receivable, net

    60,482

    113,665

    15,742

    Inventories

    144,850

    99,768

    13,818

    Amounts due from related parties

    118,736

    179,645

    24,881

    Prepayments and other current assets, net

    508,435

    620,771

    85,976

    Total current assets

    8,983,843

    8,407,698

    1,164,454

    Non-current assets:







    Property, equipment and leasehold improvement, net

    77,358

    69,973

    9,691

    Intangible assets, net

    69,778

    65,004

    9,003

    Long-term investments, net

    8,000

    8,000

    1,108

    Deferred tax assets, net

    58,263

    58,263

    8,069

    Right-of-use assets, net

    52,562

    47,708

    6,607

    Long-term bank deposits, net

    1,757,804

    1,624,802

    225,032

    Long-term investment securities, net

    5,236,109

    5,669,997

    785,286

    Goodwill

    66,506

    64,136

    8,883

    Other non-current assets, net

    4,874

    11,746

    1,627

    Total non-current assets

    7,331,254

    7,619,629

    1,055,306

    Total assets

    16,315,097

    16,027,327

    2,219,760









    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts and notes payable

    266,426

    213,849

    29,618

    Contract liabilities

    49,586

    15,058

    2,086

    Salary and welfare benefits payable

    39,256

    50,620

    7,011

    Taxes payable

    77,164

    106,658

    14,772

    Accrued expenses and other current liabilities

    103,996

    118,805

    16,454

    Amounts due to related parties

    101,927

    63,141

    8,745

    Dividend payable

    881

    -

    -

    Lease liabilities - current portion

    29,435

    31,093

    4,306

    Total current liabilities

    668,671

    599,224

    82,992









    Non-current liabilities:







    Deferred tax liabilities

    23,591

    22,584

    3,128

    Lease liabilities - non-current portion

    24,419

    17,968

    2,489

    Total non-current liabilities

    48,010

    40,552

    5,617

    Total liabilities

    716,681

    639,776

    88,609

















    Shareholders' Equity:







    Total RLX Technology Inc. shareholders' equity

    15,609,393

    15,397,603

    2,132,543

    Noncontrolling interests

    (10,977)

    (10,052)

    (1,392)

    Total shareholders' equity

    15,598,416

    15,387,551

    2,131,151









    Total liabilities and shareholders' equity

    16,315,097

    16,027,327

    2,219,760

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

    COMPREHENSIVE (LOSS)/INCOME

    (All amounts in thousands, except for number of shares and per share data, or otherwise noted)





    For the three months ended



    March 31,

    December 31,

    March 31,

    March 31,



    2023

    (As adjusted) (a)

    2023

    2024

    2024



    RMB

    RMB

    RMB

    US$











    Net revenues

    188,877

    520,468

    551,623

    76,399

    Cost of revenues

    (78,693)

    (327,325)

    (327,610)

    (45,373)

    Excise tax on products

    (64,458)

    (69,730)

    (81,240)

    (11,252)

    Gross profit

    45,726

    123,413

    142,773

    19,774











    Operating expenses:









    Selling expenses

    (85,761)

    (37,985)

    (52,887)

    (7,325)

    General and administrative expenses

    (256,504)

    (204,030)

    (109,954)

    (15,228)

    Research and development expenses

    (76,682)

    (21,904)

    (31,540)

    (4,368)

    Total operating expenses

    (418,947)

    (263,919)

    (194,381)

    (26,921)











    Loss from operations

    (373,221)

    (140,506)

    (51,608)

    (7,147)











    Other income:









    Interest income, net

    148,803

    157,928

    158,858

    22,002

    Investment income

    21,385

    182,699

    12,776

    1,769

    Others, net

    129,157

    30,925

    28,943

    4,009

    (Loss)/income before income tax

    (73,876)

    231,046

    148,969

    20,633

    Income tax benefit/(expense)  

    17,571

    (15,078)

    (16,344)

    (2,264)

    Net (loss)/income

    (56,305)

    215,968

    132,625

    18,369

    Less: net income attributable to noncontrolling interests

    661

    2,491

    717

    99

    Net (loss)/income attributable to RLX Technology Inc.

    (56,966)

    213,477

    131,908

    18,270











    Other comprehensive (loss)/income:









    Foreign currency translation adjustments

    (148,096)

    (132,470)

    12,706

    1,760

    Unrealized income/(loss) on long-term investment securities

    2,873

    (11,288)

    (13)

    (2)

    Total other comprehensive (loss)/income

    (145,223)

    (143,758)

    12,693

    1,758

    Total comprehensive (loss)/income

    (201,528)

    72,210

    145,318

    20,127

    Less: total comprehensive income attributable to 

        noncontrolling interests

    661

    2,491

    730

    101

    Total comprehensive (loss)/income attributable to RLX

        Technology Inc.

    (202,189)

    69,719

    144,588

    20,026











     Net (loss)/income per ordinary share/ADS 









    - Basic

    (0.043)

    0.166

    0.106

    0.015

    - Diluted

    (0.043)

    0.161

    0.101

    0.014











     Weighted average number of ordinary shares/ADSs









    - Basic

    1,316,798,713

    1,285,752,182

    1,249,317,641

    1,249,317,641

    - Diluted

    1,316,798,713

    1,324,466,240

    1,301,431,007

    1,301,431,007



    Note (a): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with

    ASC 805-50. The Company retrospectively adjusted the above comparative unaudited condensed consolidated
    statements of comprehensive (loss)/income in prior

    quarter.

     

    RLX TECHNOLOGY INC.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, except for number of shares and per share data)





    For the three months ended



    March 31,

    December 31,

    March 31,

    March 31,



    2023

    (As adjusted) (b)

    2023

    2024

    2024



    RMB

    RMB

    RMB

    US$

    Net (loss)/income

    (56,305)

    215,968

    132,625

    18,369

    Add: share-based compensation expenses









           Selling expenses

    23,955

    12,128

    4,603

    638

           General and administrative expenses

    201,343

    194,153

    66,414

    9,198

           Research and development expenses

    14,654

    10,335

    3,881

    538

    Non-GAAP net income

    183,647

    432,584

    207,523

    28,743











    Net (loss)/income attributable to RLX Technology Inc.

    (56,966)

    213,477

    131,908

    18,270

    Add: share-based compensation expenses

    239,952

    216,616

    74,898

    10,374

    Non-GAAP net income attributable to RLX Technology Inc.

    182,986

    430,093

    206,806

    28,644











    Non-GAAP net income per ordinary share/ADS









    - Basic

    0.139

    0.335

    0.166

    0.023

    - Diluted

    0.136

    0.325

    0.159

    0.022

    Weighted average number of ordinary shares/ADSs









    - Basic

    1,316,798,713

    1,285,752,182

    1,249,317,641

    1,249,317,641

    - Diluted

    1,345,828,279

    1,324,466,240

    1,301,431,007

    1,301,431,007











    Note (b): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with

    ASC 805-50. The Company retrospectively adjusted the above unaudited reconciliation of GAAP and Non-GAAP results in prior
    quarter.

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

    CASH FLOWS

    (All amounts in thousands)













    For the three months ended



    March 31,

    December 31,

    March 31,

    March 31,



    2023

    (As adjusted) (c)

    2023

    2024

    2024



    RMB

    RMB

    RMB

    US$











    Net cash (used in)/generated from operating activities

    (230,686)

    305,197

    4,020

    557

    Net cash generated from investing activities

    381,954

    310,274

    420,665

    58,261

    Net cash generated from/(used in) financing activities

    4,346

    (791,905)

    (472,885)

    (65,495)

    Effect of foreign exchange rate changes on cash, cash equivalents and

        restricted cash

    10,409

    (18,544)

    2,903

    404

    Net increase/(decrease) in cash and cash equivalents and restricted cash

    166,023

    (194,978)

    (45,297)

    (6,273)

    Cash, cash equivalents and restricted cash at the beginning of the period

    1,289,086

    2,615,036

    2,420,058

    335,174

    Cash, cash equivalents and restricted cash at the end of the period

    1,455,109

    2,420,058

    2,374,761

    328,901



    Note (c): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with

    ASC 805-50. The Company retrospectively adjusted the above comparative unaudited condensed consolidated statements of cash flows in prior quarter.

     

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-first-quarter-2024-financial-results-302148615.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RLX Technology downgraded by Citigroup with a new price target

      Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

      3/17/25 7:42:34 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • UBS initiated coverage on RLX Technology with a new price target

      UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

      8/8/23 9:12:45 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Files 2024 Annual Report on Form 20-F

      SHENZHEN, China, April 17, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC") on April 17, 2025. The annual report on Form 20-F can be accessed on the SEC's website at https://www.sec.gov and on the Company's investor relations website at https://ir.relxtech.com. The Company will provide a hard copy of its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. About RLX Technology Inc. RLX Techno

      4/17/25 8:00:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Financials

    Live finance-specific insights

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 14, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on March 14, 2025 - SHENZHEN, China, March 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before the U.S. markets open on Friday, March 14, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412

      3/3/25 10:30:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/7/24 6:06:29 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/6/24 4:01:28 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/14/23 6:01:42 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    SEC Filings

    See more
    • SEC Form 20-F filed by RLX Technology Inc.

      20-F - RLX Technology Inc. (0001828365) (Filer)

      4/17/25 4:01:47 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      3/14/25 6:10:16 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      11/15/24 4:01:25 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care